Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 165

1.

Effects of the tumor necrosis factor-α antagonist adalimumab on arterial inflammation assessed by positron emission tomography in patients with psoriasis: results of a randomized controlled trial.

Bissonnette R, Tardif JC, Harel F, Pressacco J, Bolduc C, Guertin MC.

Circ Cardiovasc Imaging. 2013 Jan 1;6(1):83-90. doi: 10.1161/CIRCIMAGING.112.975730. Epub 2012 Nov 30.

2.
3.

A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.

Gordon KB, Duffin KC, Bissonnette R, Prinz JC, Wasfi Y, Li S, Shen YK, Szapary P, Randazzo B, Reich K.

N Engl J Med. 2015 Jul 9;373(2):136-44. doi: 10.1056/NEJMoa1501646.

4.

Effect of the TNF-α inhibitor adalimumab in patients with recalcitrant sarcoidosis: a prospective observational study using FDG-PET.

Milman N, Graudal N, Loft A, Mortensen J, Larsen J, Baslund B.

Clin Respir J. 2012 Oct;6(4):238-47. doi: 10.1111/j.1752-699X.2011.00276.x. Epub 2012 Feb 13.

PMID:
22128762
5.

Efficacy of adalimumab in the treatment of psoriasis: a retrospective study of 15 patients in daily practice.

Sola-Ortigosa J, Sánchez-Regaña M, Umbert-Millet P.

J Dermatolog Treat. 2012 Jun;23(3):203-7. doi: 10.3109/09546634.2010.519376. Epub 2011 Jul 25.

PMID:
21787203
6.

Effect of long-term homocysteine reduction with B vitamins on arterial wall inflammation assessed by fluorodeoxyglucose positron emission tomography: a randomised double-blind, placebo-controlled trial.

Potter K, Lenzo N, Eikelboom JW, Arnolda LF, Beer C, Hankey GJ.

Cerebrovasc Dis. 2009;27(3):259-65. doi: 10.1159/000199463. Epub 2009 Feb 6.

PMID:
19202330
7.

Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial.

Leonardi C, Langley RG, Papp K, Tyring SK, Wasel N, Vender R, Unnebrink K, Gupta SR, Valdecantos WC, Bagel J.

Arch Dermatol. 2011 Apr;147(4):429-36. doi: 10.1001/archdermatol.2010.384. Epub 2010 Dec 20.

PMID:
21173304
8.

Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE.

Ortonne JP, Chimenti S, Reich K, Gniadecki R, Sprøgel P, Unnebrink K, Kupper H, Goldblum O, Thaçi D.

J Eur Acad Dermatol Venereol. 2011 Sep;25(9):1012-20. doi: 10.1111/j.1468-3083.2010.03944.x. Epub 2011 Jan 9.

PMID:
21214631
9.

Association of adiponectin, resistin, and vascular inflammation: analysis with 18F-fluorodeoxyglucose positron emission tomography.

Choi HY, Kim S, Yang SJ, Yoo HJ, Seo JA, Kim SG, Kim NH, Baik SH, Choi DS, Choi KM.

Arterioscler Thromb Vasc Biol. 2011 Apr;31(4):944-9. doi: 10.1161/ATVBAHA.110.220673. Epub 2011 Jan 6.

10.

Effect of adalimumab on sleep parameters in patients with psoriasis and obstructive sleep apnea: a randomized controlled trial.

Maari C, Bolduc C, Nigen S, Marchessault P, Bissonnette R.

J Dermatolog Treat. 2014 Feb;25(1):57-60. doi: 10.3109/09546634.2012.713458. Epub 2012 Sep 19.

PMID:
22834968
11.

Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial.

Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, D'Haens G, Li J, Rosenfeld MR, Kent JD, Pollack PF.

Ann Intern Med. 2007 Jun 19;146(12):829-38. Epub 2007 Apr 30.

PMID:
17470824
12.

Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT): a pilot study.

Mehta NN, Yu Y, Saboury B, Foroughi N, Krishnamoorthy P, Raper A, Baer A, Antigua J, Van Voorhees AS, Torigian DA, Alavi A, Gelfand JM.

Arch Dermatol. 2011 Sep;147(9):1031-9. doi: 10.1001/archdermatol.2011.119. Epub 2011 May 16.

13.

Vascular inflammation in patients with impaired glucose tolerance and type 2 diabetes: analysis with 18F-fluorodeoxyglucose positron emission tomography.

Kim TN, Kim S, Yang SJ, Yoo HJ, Seo JA, Kim SG, Kim NH, Baik SH, Choi DS, Choi KM.

Circ Cardiovasc Imaging. 2010 Mar;3(2):142-8. doi: 10.1161/CIRCIMAGING.109.888909. Epub 2010 Jan 8.

14.

Relationship of serum inflammatory biomarkers with plaque inflammation assessed by FDG PET/CT: the dal-PLAQUE study.

Duivenvoorden R, Mani V, Woodward M, Kallend D, Suchankova G, Fuster V, Rudd JH, Tawakol A, Farkouh ME, Fayad ZA.

JACC Cardiovasc Imaging. 2013 Oct;6(10):1087-94. doi: 10.1016/j.jcmg.2013.03.009.

15.

Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a Phase II/III randomized controlled study.

Asahina A, Nakagawa H, Etoh T, Ohtsuki M; Adalimumab M04-688 Study Group.

J Dermatol. 2010 Apr;37(4):299-310. doi: 10.1111/j.1346-8138.2009.00748.x.

PMID:
20507398
16.

Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis.

Revicki DA, Willian MK, Menter A, Gordon KB, Kimball AB, Leonardi CL, Langley RG, Kimel M, Okun M.

J Dermatolog Treat. 2007;18(6):341-50.

PMID:
18058494
17.

Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosis.

Elkhawad M, Rudd JH, Sarov-Blat L, Cai G, Wells R, Davies LC, Collier DJ, Marber MS, Choudhury RP, Fayad ZA, Tawakol A, Gleeson FV, Lepore JJ, Davis B, Willette RN, Wilkinson IB, Sprecher DL, Cheriyan J.

JACC Cardiovasc Imaging. 2012 Sep;5(9):911-22. doi: 10.1016/j.jcmg.2012.02.016.

18.

The prevalence of inflammation in carotid atherosclerosis: analysis with fluorodeoxyglucose-positron emission tomography.

Tahara N, Kai H, Nakaura H, Mizoguchi M, Ishibashi M, Kaida H, Baba K, Hayabuchi N, Imaizumi T.

Eur Heart J. 2007 Sep;28(18):2243-8. Epub 2007 Aug 5.

19.

Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION).

Saurat JH, Stingl G, Dubertret L, Papp K, Langley RG, Ortonne JP, Unnebrink K, Kaul M, Camez A; CHAMPION Study Investigators.

Br J Dermatol. 2008 Mar;158(3):558-66. Epub 2007 Nov 28.

PMID:
18047523
Items per page

Supplemental Content

Write to the Help Desk